MedTrace Logo

On Dose Efficiency of Modern CT-scanners in Chest Scans

NCT04996693 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 958

Last updated 2023-11-22

No results posted yet for this study

Summary

CT scans of the chest / thorax are of great importance both in the initial diagnosis and in the follow-up of pulmonary or thoracic diseases. As an example, CT angiography of the pulmonary arteries (CTPA) is worldwide considered to be gold standard test in patients with a suspicion for pulmonary embolism.

The aim of this study is to measure and compare dose efficiency of modern CT scanners for unenhanced and contrast-enhanced scan protocols of the chest/thorax. Patients who are referred for a CT of the chest/thorax will be randomly assigned to one of the three CT scanners currently in use at our institution.

Conditions

Interventions

DIAGNOSTIC_TEST

Imaging on Scanner with Spectral Imaging Capabilities

Patients will undergo imaging on a modern CT scanner with spectral imaging capabilities. A dose neutral spectral acquisition mode will routinely be used. Contrast material protocol and scan ranges are similar in all three arms.

DIAGNOSTIC_TEST

CT Scan using an Energy-Integrating Detector CT (128 slice MDCT)

Patients will undergo imaging on a modern 128-slice CT scanner (Siemens Healthineers) with energy-integrating detector and without spectral acquisition mode. Contrast material protocol and scan ranges are similar in all three arms.

DIAGNOSTIC_TEST

CT Scan using an Energy-Integrating Detector CT (20-slice MDCT)

Patients will undergo imaging on a modern 20-slice CT scanner (Siemens Healthineers) with energy-integrating detector and without spectral acquisition mode. Contrast material protocol and scan ranges are similar in all three arms.

Sponsors & Collaborators

  • University Hospital Augsburg

    lead OTHER

Principal Investigators

  • Florian Schwarz, MD · Universitaetsklinikum Augsburg

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-07
Primary Completion
2023-05-31
Completion
2023-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04996693 on ClinicalTrials.gov